Detention of HPV L1 Capsid Protein and HTERC Gene in Screening of Cervical Cancer

Overview

Journal Iran J Basic Med Sci

Publisher Mashhad University of Medical Sciences

Specialty General Medicine

Date 2013 Sep 3

PMID 23997907

Citations 7

Authors

Huang Bin

Wu Ruifang

Li Ruizhen

Liang Yiheng

Liu Zhihong

Li Juan

Wang Chun

Zhou Yanqiu

Weng Leiming

Affiliations

Soon will be listed here.

Abstract

Objective(s): To investigate the expression of human papilloma virus (HPV) L1 capsid protein, and human telomerase RNA component (hTERC) in cervical cancer and the role of detection of both genes in screening of cervical cancer.

Materials And Methods: A total of 309 patients were recruited and cervical exfoliated cells were collected. Immunocytochemistry was employed to detect HPV L1 capsid protein, and fluorescent in situ hybridization (FISH) was performed to detect the hTERC.

Results: The expression of HPV L1 capsid protein reduced with the increase of the histological grade of cervical cells and was negatively related to the grade of cervical lesions. However, the expression of hTERC increased with the increase of the histological grade and positively associated with the grade of cervical lesions. The proportion of patients with L1(-)/hTERC(+) was higher in patients with histological grade of CIN2 or higher than that in those with histological grade of CIN1. The L1(+)/hTERC(-) and L1(-)/hTERC(-) were negatively related to the grade of cervical lesions. L1(-)/hTERC(+) was positively associated with the grade of cervical lesions. The L1/hTERC ratio increased. The negative predictive value of both HPV L1 and hTERC was higher than that of HPV L1 or hTERC, but there was no marked difference in the screening efficacy of cervical cancer among HPV L1, hTERC and HPV L1+hTERC.

Conclusion: HPV L1 capsid protein and hTERC gene may serve as markers for the early diagnosis and prediction of cervical lesions. The increase in L1/hTERC ratio reflects the progression of cervical lesions to a certain extent.

Citing Articles

The complexity of human papilloma virus in cancers: a narrative review.

Hamidi Sofiani V, Veisi P, Rezaei Zadeh Rukerd M, Ghazi R, Nakhaie M Infect Agent Cancer. 2023; 18(1):13.

PMID: 36843070 PMC: 9969657. DOI: 10.1186/s13027-023-00488-w.

The Role of p16/Ki-67 Immunostaining, hTERC Amplification and Fibronectin in Predicting Cervical Cancer Progression: A Systematic Review.

Voidazan S, Dianzani C, Husariu M, Gered B, Turdean S, Uzun C Biology (Basel). 2022; 11(7).

PMID: 36101337 PMC: 9312145. DOI: 10.3390/biology11070956.

Human papillomavirus and human telomerase RNA component gene in cervical cancer progression.

Liu Y, Fan P, Yang Y, Xu C, Huang Y, Li D Sci Rep. 2019; 9(1):15926.

PMID: 31685833 PMC: 6828729. DOI: 10.1038/s41598-019-52195-5.

Genomic amplification of HPV, h-TERC and c-MYC in liquid-based cytological specimens for screening of cervical intraepithelial neoplasia and cancer.

Ji W, Lou W, Hong Z, Qiu L, Di W Oncol Lett. 2019; 17(2):2099-2106.

PMID: 30675277 PMC: 6341815. DOI: 10.3892/ol.2018.9825.

Pseudomonas aeruginosa mannose-sensitive hemagglutinin inhibits proliferation and invasion via the PTEN/AKT pathway in HeLa cells.

Yin T, Ou-Yang X, Jiao F, Huang L, Tang X, Ren B Oncotarget. 2016; 7(24):37121-37131.

PMID: 27206797 PMC: 5095063. DOI: 10.18632/oncotarget.9467.

References

Hilfrich R, Hariri J . Prognostic relevance of human papillomavirus L1 capsid protein detection within mild and moderate dysplastic lesions of the cervix uteri in combination with p16 biomarker. Anal Quant Cytol Histol. 2008; 30(2):78-82. View

Kawai K, Yaginuma Y, Tsuruoka H, Griffin M, Hayashi H, Ishikawa M . Telomerase activity and human papillomavirus (HPV) infection in human uterine cervical cancers and cervical smears. Eur J Cancer. 1999; 34(13):2082-6. DOI: 10.1016/s0959-8049(98)00242-1. View

McMurray H, Nguyen D, Westbrook T, McAnce D . Biology of human papillomaviruses. Int J Exp Pathol. 2001; 82(1):15-33. PMC: 2517699. DOI: 10.1046/j.1365-2613.2001.00177.x. View

James M, Lee J, Klingelhutz A . Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner. J Virol. 2006; 80(11):5301-7. PMC: 1472131. DOI: 10.1128/JVI.01942-05. View

Andersson S, Wallin K, Hellstrom A, Morrison L, Hjerpe A, Auer G . Frequent gain of the human telomerase gene TERC at 3q26 in cervical adenocarcinomas. Br J Cancer. 2006; 95(3):331-8. PMC: 2360637. DOI: 10.1038/sj.bjc.6603253. View

Rao P, Arias-Pulido H, Lu X, Harris C, Vargas H, Zhang F . Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. BMC Cancer. 2004; 4:5. PMC: 356916. DOI: 10.1186/1471-2407-4-5. View

Ferber M, Montoya D, Yu C, Aderca I, McGee A, Thorland E . Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene. 2003; 22(24):3813-20. DOI: 10.1038/sj.onc.1206528. View

Caraway N, Khanna A, Dawlett M, Guo M, Guo N, Lin E . Gain of the 3q26 region in cervicovaginal liquid-based pap preparations is associated with squamous intraepithelial lesions and squamous cell carcinoma. Gynecol Oncol. 2008; 110(1):37-42. DOI: 10.1016/j.ygyno.2008.01.040. View

Melnikow J, Nuovo J, Willan A, Chan B, HOWELL L . Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998; 92(4 Pt 2):727-35. DOI: 10.1016/s0029-7844(98)00245-2. View

10.

Hagensee M, Koutsky L, Lee S, Grubert T, Kuypers J, Kiviat N . Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions. J Infect Dis. 2000; 181(4):1234-9. DOI: 10.1086/315364. View

11.

Arafa M, Boniver J, Delvenne P . Detection of HPV-induced cervical (pre) neoplastic lesions: a tissue microarray (TMA) study. Appl Immunohistochem Mol Morphol. 2008; 16(5):422-32. DOI: 10.1097/PAI.0b013e318166fd42. View

12.

Yang Y, Shyong W, Chang M, Chen Y, Lin C, Huang Z . Frequent gain of copy number on the long arm of chromosome 3 in human cervical adenocarcinoma. Cancer Genet Cytogenet. 2001; 131(1):48-53. DOI: 10.1016/s0165-4608(01)00510-6. View

13.

Munger K, Baldwin A, Edwards K, Hayakawa H, Nguyen C, Owens M . Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004; 78(21):11451-60. PMC: 523272. DOI: 10.1128/JVI.78.21.11451-11460.2004. View

14.

Sui W, Ou M, Dai Y, Chen J, Lan H, Yan Q . Gain of the human telomerase RNA gene TERC at 3q26 is strongly associated with cervical intraepithelial neoplasia and carcinoma. Int J Gynecol Cancer. 2009; 19(8):1303-6. DOI: 10.1111/IGC.0b013e3181b62ea5. View

15.

Roden R, Wu T . How will HPV vaccines affect cervical cancer?. Nat Rev Cancer. 2006; 6(10):753-63. PMC: 3181152. DOI: 10.1038/nrc1973. View

16.

Hopman A, Theelen W, Hommelberg P, Kamps M, Herrington C, Morrison L . Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer. J Pathol. 2006; 210(4):412-9. DOI: 10.1002/path.2070. View

17.

Lee H, Lee K, Jung C, Hong J, Lee Y, Choi Y . Expression of HPV L1 capsid protein in cervical specimens with HPV infection. Diagn Cytopathol. 2008; 36(12):864-7. DOI: 10.1002/dc.20922. View

18.

Dehn D, Torkko K, Shroyer K . Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. Cancer. 2007; 111(1):1-14. DOI: 10.1002/cncr.22425. View

19.

Cao Y, Bryan T, Reddel R . Increased copy number of the TERT and TERC telomerase subunit genes in cancer cells. Cancer Sci. 2008; 99(6):1092-9. PMC: 11158516. DOI: 10.1111/j.1349-7006.2008.00815.x. View

20.

Allen D, White D, Hutchins A, Scurry J, Tabrizi S, Garland S . Progressive genetic aberrations detected by comparative genomic hybridization in squamous cell cervical cancer. Br J Cancer. 2000; 83(12):1659-63. PMC: 2363460. DOI: 10.1054/bjoc.2000.1509. View